These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 19592461)
21. Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Li D; Laubach VE; Johns RA Am J Physiol Lung Cell Mol Physiol; 2001 Aug; 281(2):L369-76. PubMed ID: 11435211 [TBL] [Abstract][Full Text] [Related]
26. Protein kinase G phosphorylates soluble guanylyl cyclase on serine 64 and inhibits its activity. Zhou Z; Sayed N; Pyriochou A; Roussos C; Fulton D; Beuve A; Papapetropoulos A Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1803-10. PubMed ID: 18635821 [TBL] [Abstract][Full Text] [Related]
27. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Oka M; Karoor V; Homma N; Nagaoka T; Sakao E; Golembeski SM; Limbird J; Imamura M; Gebb SA; Fagan KA; McMurtry IF Cardiovasc Res; 2007 Jun; 74(3):377-87. PubMed ID: 17346686 [TBL] [Abstract][Full Text] [Related]
28. Sulfhydryl-dependent dimerization of soluble guanylyl cyclase modulates the relaxation of porcine pulmonary arteries to nitric oxide. Ye L; Liu J; Liu H; Ying L; Dou D; Chen Z; Xu X; Raj JU; Gao Y Pflugers Arch; 2013 Feb; 465(2):333-41. PubMed ID: 23143201 [TBL] [Abstract][Full Text] [Related]
29. Role of integrin-linked kinase in the hypoxia-induced phenotypic transition of pulmonary artery smooth muscle cells: Implications for hypoxic pulmonary hypertension. Hou J; Liu B; Zhu B; Wang D; Qiao Y; Luo E; Nawabi AQ; Yan G; Tang C Exp Cell Res; 2019 Sep; 382(2):111476. PubMed ID: 31255599 [TBL] [Abstract][Full Text] [Related]
30. NO-independent activators of soluble guanylate cyclase: therapeutic potential. Mathew R Am J Hypertens; 2009 May; 22(5):470. PubMed ID: 19387430 [No Abstract] [Full Text] [Related]
31. Nitric oxide receptor soluble guanylyl cyclase undergoes splicing regulation in differentiating human embryonic cells. Sharin VG; Mujoo K; Kots AY; Martin E; Murad F; Sharina IG Stem Cells Dev; 2011 Jul; 20(7):1287-93. PubMed ID: 20964618 [TBL] [Abstract][Full Text] [Related]
32. NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in mice. de Frutos S; Caldwell E; Nitta CH; Kanagy NL; Wang J; Wang W; Walker MK; Gonzalez Bosc LV Am J Physiol Heart Circ Physiol; 2010 Aug; 299(2):H356-63. PubMed ID: 20495147 [TBL] [Abstract][Full Text] [Related]
33. Desensitization of the soluble guanylyl cyclase/cGMP pathway by lipopolysaccharide in rat isolated pulmonary artery but not aorta. El-Awady MS; Smirnov SV; Watson ML Br J Pharmacol; 2008 Dec; 155(8):1164-73. PubMed ID: 18806822 [TBL] [Abstract][Full Text] [Related]
34. RNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclase. Sharina IG; Cote GJ; Martin E; Doursout MF; Murad F Nitric Oxide; 2011 Oct; 25(3):265-74. PubMed ID: 21867767 [TBL] [Abstract][Full Text] [Related]
35. NFATc3 regulation of collagen V expression contributes to cellular immunity to collagen type V and hypoxic pulmonary hypertension. Sheak JR; Jones DT; Lantz BJ; Maston LD; Vigil D; Resta TC; Resta MM; Howard TA; Kanagy NL; Guo Y; Jankowska-Gan E; Sullivan JA; Braun RK; Burlingham WJ; Gonzalez Bosc LV Am J Physiol Lung Cell Mol Physiol; 2020 Dec; 319(6):L968-L980. PubMed ID: 32997513 [TBL] [Abstract][Full Text] [Related]
36. NFATc3 is required for intermittent hypoxia-induced hypertension. de Frutos S; Duling L; Alò D; Berry T; Jackson-Weaver O; Walker M; Kanagy N; González Bosc L Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H2382-90. PubMed ID: 18359899 [TBL] [Abstract][Full Text] [Related]
37. Molecular dissection of mouse soluble guanylyl cyclase alpha1 promoter. Vazquez-Padron RI; Pham SM; Pang M; Li S; Aïtouche A Biochem Biophys Res Commun; 2004 Jan; 314(1):208-14. PubMed ID: 14715267 [TBL] [Abstract][Full Text] [Related]